GT Biopharma Inc. (GTBP) 宣布,其针对GTB-5550 Trike®的研究性新药(IND)申请已获得美国食品药品监督管理局(FDA)的许可。GTB-5550 Trike®是一种靶向B7-H3的自然杀伤(NK)细胞衔接器,旨在治疗表达B7-H3的实体瘤。
GT Biopharma Inc. (GTBP) 宣布,其针对GTB-5550 Trike®的研究性新药(IND)申请已获得美国食品药品监督管理局(FDA)的许可。GTB-5550 Trike®是一种靶向B7-H3的自然杀伤(NK)细胞衔接器,旨在治疗表达B7-H3的实体瘤。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.